Receptor News and Research

RSS

Pfizer’s palbociclib Phase 2 trial achieves primary endpoint in patients with advanced breast cancer

Pfizer Inc. today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.

4 Feb 2014

Dormant prostate cancer cells in bone tissue can be reawakened, say researchers

Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute discovered in pre-clinical models that dormant prostate cancer cells found in bone tissue can be reawakened, causing metastasis to other parts of the body. Understanding this mechanism of action may allow researchers to intervene prior to disease progression.

31 Jan 2014

Trevena prices initial public offering of common stock

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share.

31 Jan 2014

Study points to gender-specific mechanisms of brain repair following oxygen deprivation

Physicians have long known that oxygen deprivation to the brain around the time of birth causes worse damage in boys than girls. Now a study by researchers from the Johns Hopkins Children’s Center conducted in mice reveals one possible reason behind this gender disparity and points to gender-specific mechanisms of brain repair following such injury.

31 Jan 2014

TSRI scientists awarded grant to develop new therapeutic approaches for lung cancer

Scientists from the Florida campus of The Scripps Research Institute have been awarded approximately $1.8 million from the National Cancer Institute of the National Institutes of Health to identify the signaling pathways that underlie lung cancer and to use this information to develop new therapeutic approaches.

30 Jan 2014

Findings on molecular defects behind bladder cancer may pave way for new, targeted treatments

The once sketchy landscape of the molecular defects behind bladder cancer now resembles a road map to new, targeted treatments thanks to the unified efforts of scientists and physicians at 40 institutions.

30 Jan 2014

Dormant prostate cancer cells within bone tissue can be reawakened to a cancerous state

Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.

29 Jan 2014

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Researchers led by Marta Barrachina, Institute of Neuropathology of the Bellvitge Biomedical Research Institute (IDIBELL) have identified a new subgroup of patients suffering from schizophrenia characterized by motor disorders.

29 Jan 2014

Researchers design semi-synthetic proteins to analyse body's vital signal processes

Proteins play a fundamental role in almost all biological processes. They consist of chains constructed of up to 20 different amino acids, and their composition, structure and function are controlled by the genetic code.

29 Jan 2014

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Using monoclonal antibodies to fight cancer is a complex, yet promising area of study. At Memorial Sloan Kettering Cancer Center, physician-scientists have focused their attention on expanding the current therapeutic antibody repertoire, and believe a newly developed platform will do just that - ultimately leading to new and innovative treatments for cancer patients with a broad range of malignancies.

29 Jan 2014

Biologists identify protein targets for next-generation of anti-HIV drugs

People infected with the Human Immunodeficiency Virus (HIV) can stave off the symptoms of AIDS thanks to drug cocktails that mainly target three enzymes produced by the virus, but resistant strains pop up periodically that threaten to thwart these drug combos.

29 Jan 2014

Everolimus fails to boost advanced NSCLC response

Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.

28 Jan 2014

South Korean lung SCC genetic secrets revealed

Close examination of DNA taken from squamous cell carcinoma of the lung in South Korean patients has identified a gene fusion that may be targeted by current treatments, scientists say.

27 Jan 2014

Study demonstrates direct effects of fragmented sleep on tumor growth

Poor-quality sleep marked by frequent awakenings can speed cancer growth, increase tumor aggressiveness and dampen the immune system's ability to control or eradicate early cancers, according to a new study published online January 21, 2014, in the journal Cancer Research.

27 Jan 2014

New data on extending the serum half-life of albumin in vivo announced by Novozymes Biopharma

...

27 Jan 2014

Researchers detect cancer cells using olfactory senses of fruit flies

A research unit in an international cooperation project, led by the Konstanz-based neurobiologist and zoologist Professor Dr. Giovanni Galizia, has been the first to demonstrate that fruit flies are able to distinguish cancer cells from healthy cells via their olfactory sense.

25 Jan 2014

Novel HER2 mutation identified in familial lung adenocarcinomas

Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas.

24 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Environmental endocrine disrupters may endanger embryonic heart valves

Exposure to environmental endocrine disrupters, such as bisphenol A, which mimic estrogen, is associated with adverse health effects. Bisphenol A is commonly found in plastic bottles and plastic food containers. New research from a team including Carnegie's Daniel Gorelick and Marnie Halpern on the effects of these chemicals on zebrafish shows that embryonic heart valves could be particularly in danger. It is published by Environmental Health Perspectives.

24 Jan 2014

Moderate radiation doses can kill premalignant cells and prevent second breast cancers

Survivors of breast cancer have a one in six chance of developing breast cancer in the other breast. But a study conducted in mice suggests that survivors can dramatically reduce that risk through treatment with moderate doses of radiation to the unaffected breast at the same time that they receive radiation therapy to their affected breast.

24 Jan 2014

Receptor News and Research

Pfizer’s palbociclib Phase 2 trial achieves primary endpoint in patients with advanced breast cancer

Dormant prostate cancer cells in bone tissue can be reawakened, say researchers

Trevena prices initial public offering of common stock

Study points to gender-specific mechanisms of brain repair following oxygen deprivation

TSRI scientists awarded grant to develop new therapeutic approaches for lung cancer

Findings on molecular defects behind bladder cancer may pave way for new, targeted treatments

Dormant prostate cancer cells within bone tissue can be reawakened to a cancerous state

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Researchers design semi-synthetic proteins to analyse body's vital signal processes

Scientists develop monoclonal antibodies that may lead to new, innovative treatments for cancer patients

Biologists identify protein targets for next-generation of anti-HIV drugs

Everolimus fails to boost advanced NSCLC response

South Korean lung SCC genetic secrets revealed

Study demonstrates direct effects of fragmented sleep on tumor growth

New data on extending the serum half-life of albumin in vivo announced by Novozymes Biopharma

Researchers detect cancer cells using olfactory senses of fruit flies

Novel HER2 mutation identified in familial lung adenocarcinomas

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Environmental endocrine disrupters may endanger embryonic heart valves

Moderate radiation doses can kill premalignant cells and prevent second breast cancers

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News